De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors

Nature Immunology

Volumn 18, Issue 11, 2017, Pages 1207-1217

  Johansson Percival, Anna ^a   He, Bo ^a   Li, Zhi Jie ^a   Kjellén, Alva ^a   Russell, Karen ^a   Li, Ji ^a   Larma, Irma ^a   Ganss, Ruth ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC AGENT; LIGHT VASCULAR TARGETING PEPTIDE; UNCLASSIFIED DRUG; CANCER VACCINE; HERPESVIRUS ENTRY MEDIATOR LIGAND; PEPTIDE; TNFSF14 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; IMMUNOLOGICAL MEMORY; MACROPHAGE; MEMORY T LYMPHOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE ACTIVATION; TERTIARY LYMPHOID STRUCTURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; AMINO ACID SEQUENCE; ANIMAL; C3H MOUSE; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; SURVIVAL ANALYSIS; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; IMMUNOTHERAPY; LYMPHOCYTES; MICE, INBRED C3H; MICE, TRANSGENIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 85031770796     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3836     Document Type: Article

References (51)

1. Galon, J. et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1 (2012).
2. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268-276 (2013).
3. Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669-682 (2015).
4. Johansson, A., Hamzah, J. & Ganss, R. More than a scaffold: Stromal modulation of tumor immunity. Biochim. Biophys. Acta 1865, 3-13 (2016).
5. Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622 (2014).
6. Dirkx, A. E. et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63, 2322-2329 (2003).
7. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414 (2008).
8. Hamzah, J. et al. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118, 1691-1699 (2008).
9. Johansson, A., Hamzah, J., Payne, C. J. & Ganss, R. Tumor-targeted TNFstabilizes tumor vessels and enhances active immunotherapy. Proc. Natl. Acad. Sci. USA 109, 7841-7846 (2012).
10. Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010).
11. Dirkx, A. E. et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20, 621-630 (2006).
12. Johansson-Percival, A. et al. Intratumoral LIGHT restores pericyte contractile properties and vessel integrity. Cell Rep. 13, 2687-2698 (2015).
13. Lu, T. T. & Browning, J. L. Role of the lymphotoxin/LIGHT system in the development and maintenance of reticular networks and vasculature in lymphoid tissues. Front. Immunol. 5, 47 (2014).
14. Browning, J. L. et al. Lymphotoxin-receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 23, 539-550 (2005).
15. Förster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23-33 (1999).
16. Dieu-Nosjean, M. C. et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260-275 (2016).
17. Kirk, C. J., Hartigan-O'Connor, D. & Mulé, J. J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61, 8794-8802 (2001).
18. Thompson, E. D., Enriquez, H. L., Fu, Y. X. & Engelhard, V. H. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207, 1791-1804 (2010).
19. Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M. & Swartz, M. A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749-752 (2010).
20. Joshi, N. S. et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43, 579-590 (2015).
21. Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285-296 (2016).
22. Allen, E. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9, eaak96 (2017).
23. Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 9, eaak9670 (2017).
24. Yu, P. et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5, 141-149 (2004).
25. Chang, Y. H., Hsieh, S. L., Chao, Y., Chou, Y. C. & Lin, W. W. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells. J. Biomed. Sci. 12, 363-375 (2005).
26. Ruoslahti, E., Bhatia, S. N. & Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759-768 (2010).
27. Johansson, A., Hamzah, J. & Ganss, R. License for destruction: Tumor-specific cytokine targeting. Trends Mol. Med. 20, 16-24 (2014).
28. Mazzone, M. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851 (2009).
29. Cantelmo, A. R. et al. Inhibition of the glycolytic activator PFKFB3 in Endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell 30, 968-985 (2016).
30. Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy Sci. Rep. 2, 765 (2012).
31. Onder, L. et al. Endothelial cell-specific lymphotoxin-receptor signaling is critical for lymph node and high endothelial venule formation. J. Exp. Med. 210, 465-473 (2013).
32. Fan, L., Reilly, C. R., Luo, Y., Dorf, M. E. & Lo, D. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J. Immunol. 164, 3955-3959 (2000).
33. Förster, I., Hirose, R., Arbeit, J. M., Clausen, B. E. & Hanahan, D. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity 2, 573-585 (1995).
34. Garbi, N., Arnold, B., Gordon, S., Hämmerling, G. J. & Ganss, R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172, 5861-5869 (2004).
35. Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107, 4275-4280 (2010).
36. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185-202 (2014).
37. Ganss, R., Ryschich, E., Klar, E., Arnold, B. & Hämmerling, G. J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62, 1462-1470 (2002).
38. Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589-602 (2013).
39. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
40. Hiraoka, N. et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782-1790 (2015).
41. Bento, D. C. et al. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4, e974374 (2015).
42. Fisher, D. T. et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121, 3846-3859 (2011).
43. Peske, J. D. et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).
44. Guedj, K. et al. M1 macrophages act as LTR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc. Res. 101, 434-443 (2014).
45. Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402-1410 (2016).
46. Ganss, R. & Hanahan, D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58, 4673-4681 (1998).
47. Schrama, D. et al. Targeting of lymphotoxin-to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14, 111-121 (2001).
48. Maldonado, L. et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci. Transl. Med. 6, 221ra13 (2014).
49. Lutz, E. R. et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2, 616-631 (2014).
50. Joyce, J. A. et al. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4, 393-403 (2003).
51. Agemy, L. et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci. USA 108, 17450-17455 (2011).